Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
61.93
-1.97 (-3.08%)
At close: May 15, 2026, 4:00 PM EDT
61.74
-0.19 (-0.31%)
After-hours: May 15, 2026, 7:43 PM EDT

Oruka Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2023FY 2022FY 2021FY 2020
Period Ending
Mar '26 Dec '25 Dec '23 Dec '22 Dec '21 Dec '20
Selling, General & Admin
23.5421.416.285.855.54.77
Research & Development
109.86100.641.014.7513.834.99
Total Operating Expenses
133.4122.057.310.619.349.77
Operating Income
-133.4-122.05-7.3-10.6-19.34-9.77
Interest Income
17.1416.631.960.680.010.03
Interest Expense
------0.01
Other Non-Operating Income (Expense)
0-0.01--0.01--
Total Non-Operating Income (Expense)
17.1516.621.960.670.010.02
Pretax Income
-116.25-105.43-5.34-9.93-19.32-9.75
Provision for Income Taxes
------0.01
Net Income
-116.25-105.43-5.34-9.93-19.32-9.74
Net Income to Common
-116.25-105.43-5.34-9.93-19.32-9.74
Shares Outstanding (Basic)
49461110
Shares Outstanding (Diluted)
49461110
Shares Change (YoY)
210.55%3697.00%0.04%3.64%195.19%256.50%
EPS (Basic)
-1.94-1.85-4.44-8.28-16.68-24.84
EPS (Diluted)
-1.94-1.85-4.44-8.28-16.68-24.84
Shares Outstanding
61.660.151.2114.4114.419.55
Free Cash Flow
-91.19-88.42-5.01-10.91-18.81-7.74
Free Cash Flow Per Share
-1.86-1.94-4.17-9.09-16.23-19.73
EBITDA
-133.32-121.97-7.28-10.58-19.32-9.76
EBIT
-133.4-122.05-7.3-10.6-19.34-9.77
Effective Tax Rate
-0.00%0.00%0.00%0.00%0.09%
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q